- Theratechnologies press release ( NASDAQ: THTX ): Q4 GAAP EPS of -$0.09 misses by $0.02 .
- Revenue of $21.4M (+14.1% Y/Y) misses by $0.21M .
- FY2023 operating plan to focus on achieving positive Adjusted EBITDA by year end based on commercial business growth and tighter budget controls.
- Our anticipated FY2023 revenue guidance range is set between $90 million and $95 million vs $93.98M consensus, or growth of the commercial portfolio in the range of 13% and 19%, as compared to the 2022 fiscal year results.
For further details see:
Theratechnologies reports Q4 earnings miss; initiates FY23 outlook